Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516553 · ClinicalTrials.gov registry record · Phase 1
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT02516553 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 174 participants.
The verdict
NCT02516553, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful. In some countries, adolescents who are at least 15 years old and who are diagnosed with NUT carcinoma can also participate. No standard treatment exists for this rare and aggressive form of cancer. The purpose of this study is to find out the highest dose of BI 894999 that people can tolerate. BI 894999 is tested for the first time in humans. Participants take tablets once daily. The study also tests whether participants can tolerate BI 894999 better when taken continuously or with breaks in between. Participants can stay in the study as long as they benefit from the treatment and can tolerate it. The doctors also regularly check the general health of the participants.
Interventions
- DRUG BI 894999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2021-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02516553
The ClinicalTrials.gov registry entry for NCT02516553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BI 894999 is the first listed.
NCT02516553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02516553 about?
NCT02516553 is a clinical study titled "BI 894999 First in Human Dose Finding Study in Advanced Malignancies". This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful. In some countries, adolescents who are at least 15 years old and who are diagnosed with NUT carci...
What is the current status of trial NCT02516553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2015-07-08. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT02516553?
The interventions under investigation include: BI 894999 (DRUG).
Who is sponsoring clinical trial NCT02516553?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.